Combination therapy for androgenic alopecia with antisense oligonucleotides and minoxidil

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 5994319
SERIAL NO

08837190

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Minoxidil has been shown to stimulate hair growth or inhibit the loss of hair in a number of patients beginning to develop androgenic alopecia. The mechanism by which minoxidil (2,4-pyrimidinediamine, 6-(1-piperidinyl)-3-oxide) alters the hair growth cycle is uncertain, but is thought to act by increasing vascular circulation to the hair follicle. Inhibitors of steroid metabolism, particularly those that inhibit the conversion of testosterone to dihydrotestosterone, have shown effects on hair cycles, including inhibition of hair loss. One class of enzymes targeted by these inhibitors are the steroid 5-alpha reductases. Minoxidil used in conjunction with effectors of steroid metabolism, leads to enhanced hair growth and decreased rates of hair loss. This specification relates to the use of antisense oligonucleotides targeting 5-alpha reductases used in conjunction with other hair growth enhancers and/or hair loss inhibitors.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • DYAD PHARMACEUTICAL CORPORATION

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Hoke, Jr Glenn D Mount Airy, MD 1 3

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation